CAB Portfolio

ADC's &
Immune Checkpoint Inhibitors
CAR-T & Bispecifics
16 Additional
Antibody Drug Conjugates & Naked mAbs
CAB-ADC antibodies aim to address the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on cancer cells, but not to the same antigens expressed on normal cells in non-diseased tissues. This approach allows the preferential targeting of tumor tissues by ADCs, thereby increasing the efficacy to toxicity ratios (Therapeutic Index) of CAB-ADCs relative to their conventional counterparts. The use of CAB antibodies as payload delivery vehicles could dramatically increase the safety and number of tumor-associated antigens that are addressable with ADC technology.

Naked monoclonal antibodies or mAbs bind to specific epitopes or target molecules on cells.  Therapeutic uses of mAbs have been limited by several factors, including cancer cell specificity, tumor penetration, as well as manufacturing issues.  BioAtla’s human CAB mAbs are optimized and expressed in our proprietary CIAO! system.  CAB mAbs have a high Therapeutic Index because they are only active under the physiological conditions associated with disease.  This unique capability enables development of therapeutics for targets that are also expressed on healthy tissues, while minimizing undesirable side effects. 

Representative Cancer Indications
AXL is a receptor tyrosine kinase and oncogene involved in the stimulation of cell proliferation and associated with a variety of cancers including pancreatic, colon cancer, melanoma, CML and others. Like many cancer targets AXL is over-expressed in cancer but can also be found in some normal tissues, which would cause toxicity if treated with conventional Antibody Drug Conjugates (ADC’s). BioAtla’s CAB anti-AXL ADC however specifically targets the tumor microenvironment, reducing toxicity in normal tissue.
Immune Checkpoint Inhibitors
BioAtla®’s CAB immune Checkpoint inhibitors and stimulators (CAB-C’s) are engineered to target either immune cells or tumor cells. CAB-C’s are active in selected microenvironments within the body and prevent tumor cells from inhibiting immune cells, thereby enabling the body's immune cells to remain activated. These activated immune cells can shrink the tumor, individually or in combination with other drugs, and may eradicate the cancer.
Representative Cancer Indications
Non small cell lung cancer (NSCLC)
Cytotoxic T Lymphocyte Associated Protein-4 (CTLA-4) is a receptor on the surface of helper T cells that binds CD80 and CD86 on antigen presenting cells, transmitting an inhibitory signal to T cells. By reversing that inhibition, traditional anti-CTLA-4 antibodies can help treat cancer but can also cause toxicity, especially in combination with other immune checkpoint antibodies. BioAtla’s CAB anti-CTLA4 antibody can help reduce this on-target toxicity, while activating the immune system specifically in the tumor microenvironment, and therefore potentially enabling a number of combination therapies.
CAR-T & Bispecifics

BioAtla®’s conditionally active Chimeric Antigen Receptor-T cell (CAR-T’s) are drugs engineered by grafting single-chain variable fragments (scFv) from a Conditionally Active Biologic (CAB) antibody with a T cell signaling domain. These fusion molecules trigger T cell recognition and killing of cells expressing the cancer target. The CAB-derived CAR-Ts (CAB-T’s) increase target specificity which assists in decreasing adverse effects and improving therapeutic index.

BioAtla®’s Conditionally Active Bispecific Antibodies (CAB-B’s) are engineered to selectively target two receptors on cancer cells, or provide an alternative way of recruiting immune cells to the cancer tissue.

Representative Cancer Indications
Kidney cancer